FDA provides summaries of adverse drug experiences

被引：0
|
作者：
不详
机构：
来源：
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION | 2008年 / 233卷 / 05期
关键词：
D O I：
暂无
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
引用
收藏
页码：685 / 685
页数：1
相关论文
共 50 条
  • [1] FDA drug approval summaries: Fulvestrant
    Bross, PF
    Cohen, MH
    Williams, GA
    Pazdur, R
    ONCOLOGIST, 2002, 7 (06): : 477 - 480
  • [2] FDA drug approval summaries: Oxaliplatin
    Ibrahim, A
    Hirschfeld, S
    Cohen, MH
    Griebel, DJ
    Williams, GA
    Pazdur, R
    ONCOLOGIST, 2004, 9 (01): : 8 - 12
  • [3] FDA drug approval summaries:: Pemetrexed (Alimta®)
    Hazarika, M
    White, RM
    Johnson, JR
    Pazdur, R
    ONCOLOGIST, 2004, 9 (05): : 482 - 488
  • [4] FDA provides fastest drug approval
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2012, 13 (07): : E287 - E287
  • [5] PATIENT INFORMATION FDA drug summaries: a simplification too far?
    Doshi, Peter
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [6] ASSESSING ADVERSE DRUG EXPERIENCES
    JONES, JK
    HERMAN, RL
    ANNALS OF INTERNAL MEDICINE, 1988, 108 (01) : 160 - 161
  • [7] FDA Encourages Reporting of Tobacco Product Adverse Experiences
    Retzky, Sandra S.
    Spring, Silver
    CHEST, 2016, 150 (06) : 1169 - 1170
  • [8] CHANGE IN FDA DEFINITION OF SERIOUS ADVERSE DRUG EVENT
    BADER, RL
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1989, 46 (06): : 1132 - 1132
  • [9] AN ADVERSE REACTION: FDA REGULATION OF GENERIC DRUG LABELING
    Stern, Mitchell Russell
    NEW YORK UNIVERSITY LAW REVIEW, 2015, 90 (06) : 2154 - 2190
  • [10] Adverse drug events reported to FDA have increased
    不详
    MOLECULAR THERAPY, 2007, 15 (11) : 1903 - 1903
12345